Beyond MiGs: A Bio-Interventional Breakthrough in Glaucoma Surgery

Click here to watch the video version of this podcast.

In this edition of The Rob & Jai Show, the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AlloFlo—a minimally invasive, tissue-based implant that activates the uveoscleral pathway.
Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses:

🔹The evolution of his career from medical device sales to surgical commercialization and C- suite leadership.
🔹Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that.
🔹The material science breakthrough that differentiates AlloFlo from past uveoscleral attempts like CyPass.
🔹The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate.
🔹Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond.

Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed.

Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.

Resources:
Dr. Rob Rothman: https://ois.net/robert-rothman-md/
Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/
Adam Szaronos: https://ois.net/adam-szaronos/